As a major cardiovascular risk factor for stroke, coronary artery disease, heart failure and end-stage renal disease, hypertension affects approximately one billion people and causes large economic burden worldwide. Cytochrome P450 3A5 (CYP3A5), belonging to the CYP3A subfamily, has been implicated in the regulation of blood pressure and may serve as a potential risk factor for the development of hypertension. Increased CYP3A5 activity could cause sodium and water retention by affecting the metabolism of cortisol in the kidneys. Furthermore, polymorphic CYP3A5 genotypes have been shown to cause differences in blood pressure response to antihypertensive drugs. Several studies have investigated the role of CYP3A5 in blood pressure response to amlodipine. However, recent data on the role of CYP3A5 in hypertension development and treatment are inconsistent. This review summarizes what is known regarding the relationship of CYP3A5 with hypertension, discusses the limitations in present studies, highlights the gaps and directs research to this field.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 25 February 2021
Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review
Heart Failure Reviews Open Access 15 January 2019
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Timberlake DS, O'Connor DT, Parmer RJ . Molecular genetics of essential hypertension: recent results and emerging strategies. Curr Opin Nephrol Hypertens 2001; 10: 71–79.
Puddu P, Puddu GM, Cravero E, Ferrari E, Muscari A . The genetic basis of essential hypertension. Acta Cardiol 2007; 62: 281–293.
Agarwal A, Williams GH, Fisher ND . Genetics of human hypertension. Trends Endocrinol Metab 2005; 16: 127–133.
Binder A . A review of the genetics of essential hypertension. Curr Opin Cardiol 2007; 22: 176–184.
Franceschini N, Reiner AP, Heiss G . Recent findings in the genetics of blood pressure and hypertension traits. Am J Hypertens 2011; 24: 392–400.
Tanira MO, Al Balushi KA . Genetic variations related to hypertension: a review. J Hum Hypertens 2005; 19: 7–19.
Ehret GB . Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep 2010; 12: 17–25.
Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162–172.
Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773–779.
Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52–59.
Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108–1114.
Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297–1300.
Lamba JK, Lin YS, Schuetz EG, Thummel KE . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–1294.
Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272.
Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294–298.
Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE study. Am J Pharmacogenomics 2005; 5: 191–195.
Zhang L, Miyaki K, Wang W, Muramatsu M . CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J Hum Hypertens 2010; 24: 345–350.
Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992; 51: 18–23.
Ghosh S, Grogan WM, Basu A, Watlington C . Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim Biophys Acta 1993; 1182: 152–156.
Ghosh SS, Basu AK, Ghosh S, Hagley R, Kramer L, Schuetz J et al. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem Pharmacol 1995; 50: 49–54.
Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927–F931.
Burk O, Wojnowski L . Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch. Pharmacol 2004; 369: 105–124.
Eichelbaum M, Burk O . CYP3A genetics in drug metabolism. Nat Med 2001; 7: 285–287.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
Wojnowski L . Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26: 192–199.
Bolbrinker J, Seeberg S, Schostak M, Kempkensteffen C, Baelde H, de Heer E et al. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele. Drug Metab Dispos 2012; 40: 639–641.
Cai J, Huang Z, Yang G, Cheng K, Ye Q, Ming Y et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. Am J Cardiovasc Drugs 2011; 11: 401–409.
Park KW, Kang J, Park JJ, Yang HM, Lee HY, Kang HJ et al. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart 2012; 98: 1366–1372.
Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di RA . CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75: 1059–1069.
Duncan RL, Grogan WM, Kramer LB, Watlington CO . Corticosterone's metabolite is an agonist for Na+ transport stimulation in A6 cells. Am J Physiol 1988; 255: F736–F748.
Matsuzaki K, Arai T, Miyazaki T, Yasuda K . Formation of 6 beta-OH-deoxycorticosterone from deoxycorticosterone by A6 cells. Steroids 1995; 60: 457–462.
Lieb W, Bolbrinker J, Doring A, Hense HW, Erdmann J, Schunkert H et al. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clin Sci (Lond) 2006; 111: 365–372.
Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE . CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 2005; 15: 737–741.
Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, Navis G . The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 2005; 15: 831–837.
Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006; 24: 923–929.
Eap CB, Bochud M, Elston RC, Bovet P, Maillard MP, Nussberger J et al. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 2007; 49: 1007–1014.
Coto E, Tavira B, Marin R, Ortega F, Lopez-Larrea C, Ruiz-Ortega M et al. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochem Biophys Res Commun 2010.
Xi B, Wang C, Liu L, Zeng T, Liang Y, Li J et al. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. Hypertens Res 2011; 34: 1216–1220.
Imaoka S, Funae Y . Hepatic and renal cytochrome P-450s in spontaneously hypertensive rats. Biochim Biophys Acta 1991; 1074: 209–213.
Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP . A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol 1998; 274: C1245–C1252.
Pinto YM, Paul M, Ganten D . Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 39: 77–88.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ . Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747–1757.
Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883–891.
Emoto C, Iwasaki K . Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 2006; 36: 219–233.
Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836–847.
Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 2005; 78: 605–618.
Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H . CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004; 75: 529–538.
Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006; 79: 590–599.
Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174: 1715–1722.
Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007; 81: 386–391.
Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007; 82: 579–585.
Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P . Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991; 34: 1838–1844.
Stopher DA, Beresford AP, Macrae PV, Humphrey MJ . The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S55–S59.
Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW . The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986; 22: 21–25.
Beresford AP, Macrae PV, Alker D, Kobylecki RJ . Biotransformation of amlodipine. Identification and synthesis of metabolites found in rat, dog and human urine/confirmation of structures by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Arzneimittelforschung 1989; 39: 201–209.
Walker DK, Humphrey MJ, Smith DA . Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica 1994; 24: 243–250.
Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80: 646–656.
Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 2010; 31: 95–103.
Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233–1235.
Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–154.
Frohlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE . Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 2004; 58: 443–444.
Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369.
Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008; 8: 6.
Brown MJ . Hypertension and ethnic group. BMJ 2006; 332: 833–836.
Bovet P, Shamlaye C, Gabriel A, Riesen W, Paccaud F . Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy. BMC Public Health 2006; 6: 9.
Kannel WB, Wolf PA, Verter J, McNamara PM . Epidemiologic assessment of the role of blood pressure in stroke: the Framingham Study. 1970. JAMA 1996; 276: 1269–1278.
van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D . The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven countries study research group. N Engl J Med 2000; 342: 1–8.
Flack JM, Neaton J, Grimm R Jr., Shih J, Cutler J, Ensrud K et al. Blood pressure and mortality among men with prior myocardial infarction.Multiple risk factor intervention trial research group. Circulation 1995; 92: 2437–2445.
Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK . The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562.
Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J . Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch. Intern. Med 1998; 158: 2007–2014.
Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S . Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341–1345.
Schwartz GL, Turner ST . Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151–160.
Kato N . Genetic analysis in human hypertension. Hypertens Res 2002; 25: 319–327.
Luft FC . Hypertension as a complex genetic trait. Semin Nephrol 2002; 22: 115–126.
This work was supported by the National Basic Research Program of China (No. 2011CB512001), the National Natural Science Foundation of China (NO. 81273594), the National Natural Science Foundation of China (NO. 81102512) and the Doctoral Research and Innovation Project of Hunan Province (No. CX2011B075).
The authors declare no conflict of interest.
About this article
Cite this article
Zhang, YP., Zuo, XC., Huang, ZJ. et al. CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens 28, 145–149 (2014). https://doi.org/10.1038/jhh.2013.67
- blood pressure
This article is cited by
Scientific Reports (2021)
Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review
Heart Failure Reviews (2019)